Vivek Subbiah: Tissue Agnostic Precision Medicine in Primary brain tumors like glioblastoma?

Vivek Subbiah shared on LinkedIn:

“Hot off the press.

What is the impact of Tissue Agnostic Precision Medicine in Primary brain tumors like glioblastoma?

Delighted to share our paper just published in Cell Press Journal Trends in Cancer: ‘Impact of tissue-agnostic approvals on management of primary brain tumors’.

Such a great honor to work with an amazing group of colleagues who are passionate to eradicate brain cancers.”

Visit the article website.
Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.